To the full analysis
Centene stock: growth
CNCCentene reported $194.78B in revenue for fiscal 2025, up 19.4% on the prior year, up 11.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
26.4%
per year from 2006 to 2025, per share 19.6%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
19.6%
per year from 2006 to 2025, per share 13.2%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 11.9% | 23.9% | 26.4% |
| Revenue per share | 15.3% | 15.3% | 19.6% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | −1.4% | 23.9% | 19.6% |
| Free cash flow per share | 1.6% | 15.2% | 13.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $2.28B | −$43.63M | $144.71M |
| 2007 | $2.77B | $73.4M | $148.3M |
| 2008 | $3.36B | $83.5M | $156.82M |
| 2009 | $4.1B | $83.67M | $165.08M |
| 2010 | $4.45B | $94.84M | $50.38M |
| 2011 | $5.21B | $111.22M | $187.99M |
| 2012 | $8.11B | $2M | $196.55M |
| 2013 | $10.86B | $165.1M | $314.69M |
| 2014 | $16.56B | $271M | $1.12B |
| 2015 | $22.76B | $355M | $508M |
| 2016 | $40.61B | $562M | $1.55B |
| 2017 | $48.38B | $828M | $1.07B |
| 2018 | $60.12B | $900M | $559M |
| 2019 | $74.64B | $1.32B | $753M |
| 2020 | $111.12B | $1.81B | $4.63B |
| 2021 | $125.98B | $1.35B | $3.3B |
| 2022 | $144.55B | $1.2B | $5.26B |
| 2023 | $154B | $2.7B | $7.25B |
| 2024 | $163.07B | $3.31B | −$490M |
| 2025 | $194.78B | −$6.67B | $4.32B |
Revenue by segment
How Centene Corp. makes its money and how that has shifted. Names are as the company reports them.
- Medicaid76%
- Commercial22%
- Other3%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Medicaid | $124.45B | $147.64B | 75.8% |
| Commercial | $33.7B | $42B | 21.6% |
| Other | $4.92B | $5.13B | 2.6% |
| Total revenue | $163.07B | $194.78B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 9 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.